Pharma

David Chang is set to depart from his role at the cell therapy maker Allogene after an eight-year tenure. In other developments, a next-generation blood disease drug faced setbacks, while an acquisition by AbbVie led to an FDA approval. These updates provide valuable insights into the pharmaceutical industry landscape and its impact on American healthcare and innovation.

David Chang is set to depart from his role at the cell therapy maker after an eight-year tenure. In other news, a next-generation blood disease drug faced setbacks while an acquisition by AbbVie led to an FDA approval, providing valuable insights for the pharma industry.

AstraZeneca and Daiichi Sankyo have received approval from the US FDA for their drug Datroway (datopotamab deruxtecan) to address metastatic TNBC. This development could potentially impact American industry and healthcare by providing a new treatment option for patients with triple-negative breast cancer.

Eli Lilly, with plans to invest over $50 billion in U.S. manufacturing, will allocate an additional $4.5 billion to enhance two out of three new production sites in Lebanon, Indiana. This investment underscores the company’s commitment to strengthening its American manufacturing presence and contributes to local production, potentially benefiting workers and boosting industrial growth.

Eli Lilly commits over $50 billion to enhance its American manufacturing presence, with $4.5 billion allocated to improve two production facilities in Lebanon, Indiana. The investment was announced during the opening ceremony of the company’s genetic medicine plant in Lebanon, marking progress in strengthening American pharmaceutical production.